Dr. Michelle E. Melisko, Assistant Clinical Professor, UCSF, Helen Diller Family Comprehensive Cancer Center, explains how drug shortages are affecting patients with breast cancer and the potential impact to cost and outcomes.
doxorubicin Hcl Liposome Injection
doxorubicin),
Dr. Melisko discusses the paclitaxel (Brand name: Taxol) shortages that have impacted the ability to start patients with clinical trials. Physiscians are being asked to prescribe alternative drugs and only use Taxol when absolutely necessary. A recommended alternate to Taxol is another albumin-bound paclitaxel; however, it is costly. Doxil () has been a more serious shortage since the middle of August. Patients were able to switch to Adriamycin (which has more toxicity and side affects. However, Dr. Melisko does not feel it will necessarily impact the long-term prognosis because there are other drugs to be given. It is stressful for the patients and physicians to not be able to rely on using a specific drug.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More